INVARIANT LLC for CIGNA CORPORATION
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Educate policymakers on issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees; pharmacy issues related to S. 1895, the Lower Health Care Costs Act; and issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BENJAMIN KLEIN | — |
| KATHRYN WISE | — |
Taxation/Internal Revenue Code TAX
Monitor issues related to P.L. 111-148, the Patient Protection and Affordable Care Act, and P.L. 111-152, the Health Care and Education Reconciliation Act; H.R. 748 / S. 684, Middle Class Health Benefits Tax Repeal Act of 2019, legislation to repeal a 40 percent ACA excise tax on certain employer-sponsored health insurance plans; S. 172 / H.R. 1398, the Health Insurance Tax (HIT) Relief Act of 2019, legislation to suspend the ACA's health insurance tax (HIT) in 2020 and 2021; and S. 80, the Jobs and Premium Protection Act, full repeal of the HIT.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BENJAMIN KLEIN | — |
| KATHRYN WISE | — |
Health Issues HCR
Monitor issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act, and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. Educate policymakers on issues related to H.R. 861, the End Surprise Billing Act, and "No Surprises Act" Discussion Draft; issues related to 42 C.F.R. Part 2, H.R. 2062, the Overdose Prevention and Patient Safety Act, and S. 1012, the Protecting Jessica Grubb's Legacy Act; issues related to S. 1895, the Lower Health Care Costs Act, including surprise billing, and transparency and information sharing in the individual and commercial markets.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BENJAMIN KLEIN | — |
| KATHRYN WISE | — |
Medicare/Medicaid MMM
Educate policymakers on issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; and proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, and closing the Part D coverage gap and direct negotiation of prescription drug prices. Monitor issues related to Pharmacy Direct and Indirect Remuneration (DIR), including H.R. 1034 / S. 640, the Phair Pricing Act of 2019, H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act, and H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act; and issues related to Medicare Part B reforms, including S. 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S. 657, the Drug Price Transparency Act; and H.R. 2115, the Public Disclosure of Drug Discounts Act. Monitor H.R. 2113, Prescription Drug STAR Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BENJAMIN KLEIN | — |
| KATHRYN WISE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.